Enthera Pharmaceuticals develops first-in-class biologics for underserved autoimmune conditions, focusing on Type 1 Diabetes and Inflammatory Bowel Disease
Enthera Pharmaceuticals develops first-in-class biologics for underserved autoimmune conditions, focusing on Type 1 Diabetes and Inflammatory Bowel Disease. Their therapeutic approach aims to preserve and re-establish organ cell function, transforming treatment paradigms for intractable autoimmune diseases.